The authors investigated the possible association between a mother's nausea during pregnancy and her child's risk for a congenital heart defect using data from the population-based Atlanta Birth Defects Case-Control Study conducted in [1982][1983]. Case infants (n = 998) had nonsyndromic congenital heart defects and control infants (n = 3,029) had no congenital defects. Nausea during pregnancy (NP) was graded in eight levels of "severity based on its onset, frequency, and duration. Level 1, the most severe NP, was associated with a lower risk for a congenital heart defect in the child (odds ratio (OR) = 0.81, 95% confidence interval (Cl) 0.67-0.99) compared with no nausea. The lower risk tended to disappear with less severe levels of nausea, and the trend was statistically significant. Overall, early NP (levels 1 to 4 combined) with use of antinausea medication, particularly Bendectin® (doxylamine, dicyclomine (dropped from the formulation in 1976), pyridoxine (vitamin B,,)), was associated with a lower risk for congenital heart defects compared with: 1) absence of nausea (OR = 0.67, 95% Cl 0.50-0.92), and 2) nausea without medication use (OR = 0.70, 95% Cl 0.50-0.94). The results suggest that pregnancy hormones and factors or, alternatively, a component of Bendectin® (most probably pyridoxine) may be important for normal heart development. These findings outline potential areas for future research on and prevention of congenital heart defects. Am J Epidemiol 1999; 149:717-25.
The etiology of many birth defects is unknown. In an attempt to identify factors associated with the risk for birth defects, events that occur during pregnancy, especially in the first trimester, have always been of interest. Congenital heart defects are the most common serious birth defects, and affect 5 to 10 children per 1,000 livebirths (1) . A common event experienced by most women during pregnancy is the nausea and vomiting of pregnancy usually referred to as morning sickness (2) (3) (4) (5) (6) or, more properly, pregnancy sickness, because nausea and vomiting are not confined only to the morning (5) . In this manuscript, the terms nausea during pregnancy (NP) and morning sickness are used interchangeably.
Women with morning sickness, especially those with vomiting, are less likely to have a spontaneous abortion (2) (3) (4) 6) . Studies on spontaneous abortions show that many of the fetuses have congenital anom-alies and very frequently congenital heart defects (7). One of the findings in the Atlanta Birth Defects CaseControl Study was a decreased risk for congenital heart defects among the children of women who took antinausea medications for NP (8) . Because any factors associated with lower risk for these defects could reveal leads for their potential prevention, we were interested in exploring further that preliminary finding. The purpose of the current study is to determine the association between maternal NP and the child's risk for a congenital heart defect. More specifically, we attempted to answer the following questions: 1) Does having nausea during pregnancy modify a woman's risk of having an infant with a congenital heart defect? 2) If so, is the risk related to the severity of nausea or to the use of antinausea medication? 3) Is the modification in the risk specific for particular congenital heart defects?
MATERIALS AND METHODS
In this study, we used a subset of data from the Atlanta Birth Defects Case-Control Study conducted in [1982] [1983] . In the Atlanta Birth Defects CaseControl Study, information was obtained from parents of case infants with birth defects and parents of randomly chosen control infants without birth defects. Case infants born from January 1, 1968 through 718 Bonevaetal. December 31, 1980 were ascertained through the Metropolitan Atlanta Congenital Birth Defects Program (MACDP), a population-based surveillance program in the five-county metropolitan Atlanta area. The MACDP identifies infants with structural birth defects diagnosed during the first year of life. Sources of information are medical records from birth hospitals, pediatric and specialty departments, cytogenetic laboratories, and vital records (9, 10) . The control infants were a random sample of all babies without birth defects born during the same period, in the same area, and frequency matched to all case babies by calendar quarter of birth, hospital of birth, and race (white or other). Details on the Atlanta Birth Defects CaseControl Study design and procedures have been published elsewhere (11, 12) .
To study the relation between maternal NP and the occurrence of congenital heart defects, we selected as case infants all liveborn and stillborn infants with congenital heart defects using the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes 745.0-747.49 (13) . Infants with patent foramen ovale, premature infants with patent ductus arteriosus, and children with congenital heart defect associated with a known syndrome, such as trisomy 21 or 18, in which cardiovascular defects are common, were excluded from the study. For brevity, in the text, we will use the term congenital heart defects instead of congenital cardiovascular defects.
Information on pregnancy history, demographic characteristics, and a variety of exposures and other variables was obtained through a telephone interview of the mothers in 1982-1983. The complete questionnaire has been published previously (12) . The following questions on nausea during pregnancy were asked: 1) "Did you have morning sickness or nausea?" 2) "In which month of pregnancy did you first have the nausea?" 3) "How many months did you have nausea?" 4) "How often did you have nausea?" 5) "Did you take any medicine for the nausea, for instance, AlkaSeltzer, Pepto-Bismol, or Bendectin?" 6) "What kind of medicine did you take?" 7) "In which week of pregnancy did you start taking it?" 8) "For how many weeks did you take it?"
On the basis of their answers to the first question, the mothers were divided into two main groups: those who reported and those who did not report nausea in pregnancy. In an attempt to quantify the nausea, we grouped mothers into different levels of nausea during pregnancy based on its time of onset, duration, and frequency. We dichotomized three original variables-onset, frequency, and duration. Onset was considered early if the nausea started within the first 2 months of pregnancy.
This time period includes the vulnerable period for heart development. Nausea reported every day was considered frequent. Nausea which lasted 2 months or more was considered of long duration. From these three sets of dichotomized variables, we defined eight levels of nausea during pregnancy. Level 1 was early, frequent, and long-lasting, and was considered the most "severe" level of nausea, while level 8 was the least "severe."
To determine whether maternal use of antinausea medication for morning sickness altered a child's risk for a congenital heart defect, we stratified the analyses by use of antinausea medication (Bendectin® (Merrell Dow Pharmaceuticals, Midland, Michigan), or other) and by the time when the medication was started (within the first 8 weeks or later). For the purpose of the analyses by individual heart defects, we used a classification of congenital heart defects similar to the one used in the Baltimore-Washington Infant Studyhierarchical allocation of the principal lesion (14) . For example, the group of ventricular septal defects does not include cases with any of the following defects: looping abnormalities (defects of heart laterality, asplenia/polysplenia syndrome, L-transposition of the great arteries), common truncus arteriosus, transposition of the great arteries, tetralogy of Fallot, hypoplastic left heart syndrome, or pulmonary or tricuspid atresia.
To estimate the relative risk of having a child with a congenital heart defect associated with a particular level of nausea, we used odds ratios and 95 percent confidence intervals. For the crude analysis, we used the Mantel-Haenszel test (or Fisher's exact test if the number in any cell was less than 5). For the multivariate analysis, we used logistic regression to adjust for possible confounders-factors previously found to be associated with birth defects (race (two strata) and education (three strata) as a substitute for socioeconomic status; previous miscarriages (five strata); maternal alcohol use during pregnancy, insulindependent diabetes mellitus, and vitamin use (from 3 months before conception through 3 months after conception); and child's year of birth (used as a continuous variable)), with NP (parity (four strata), and smoking during pregnancy) (15), or with both (maternal age (five strata)). A chi-square test was used to evaluate linear trends in proportions. The statistical packages used to calculate the odds ratios and 95 percent confidence intervals were Statistical Analysis System (SAS) for Windows, version 6.12 (SAS Institute Inc., Cary, North Carolina) and Epi-Info 6.04 (Centers for Disease Control and Prevention, Atlanta, Georgia).
RESULTS
The distribution of case and control mothers by selected sociodemographic characteristics and by Overall, reporting of nausea, without considering its severity, was not associated with a statistically significant difference in the risk of having a baby with a congenital heart defect, although the risk was slightly reduced (table 2) . We present the results of the crude analyses, because they were not appreciably different from the adjusted estimates from the multivariate model. Early, frequent, and long-lasting nausea (level 1) was associated with a lower risk of having an infant with a congenital heart defect (odds ratio (OR) = 0.81, 95 percent confidence interval (CI) 0.67-0.99). The distribution of case and control mothers in the eight levels of NP and the relative risk of having a child with a congenital heart defect are presented in table 2. These data show that as the severity of nausea decreased (level 1 to 8), the inverse association between a woman's history of NP and her child's risk for congenital heart defect tended to disappear. The test for linear trend in proportions was statistically significant: chi-square = 8.24, p = 0.004.
Because the most pronounced reduction in risk for congenital heart defects was observed among women with the most severe nausea (level 1) and since the heart development is virtually completed by the eighth week of pregnancy, our further analysis was limited to early nausea (levels 1 to 4). The stratified analysis by use of medication, starting within the first 8 weeks of pregnancy, is presented in table 3. Overall, 25.4 percent of case mothers and 29.5 percent of control mothers with early NP used antinausea medication in the first 8 weeks of pregnancy. Compared with no NP, use of antinausea medication during the first 8 weeks of pregnancy was associated with significantly lower risk for congenital heart defects for level 1 nausea and for levels 1 through 4 combined (all early NP): OR = 0.74, 95 percent CI 0.56-0.97 and OR = 0.77, 95 percent CI 0.61-0.97, respectively. Levels 2 and 3 NP were also associated with slightly lower risk but were not statistically significant.
Among mothers who took antinausea medications in the first 8 weeks of pregnancy, Bendectin® was the medication most frequently used. Its use for early NP was associated with significantly lower risk for congenital heart defect (OR = 0.67, 95 percent CI 0.50-0.92) compared with no nausea. For individual levels of nausea (1 through 4), the use of Bendectin® was also associated with lower risk but was statistically significant only for level 2.
For all mothers who reported early nausea, both the group of all medication users and the group of Bendectin® users were at a statistically significant lower risk of having children with congenital heart defects not only when compared with the referent group with no nausea (ORs presented in table 3), but even when compared with the group of women who had nausea but did not take medications: for all antinausea medications combined versus no medication use, the odds ratio was 0.80 (95 percent CI 0.64-1.00); for Bendectin® only versus no medication use, the We also determined the risk for individual congenital heart defects (table 4). For most individual defects (looping abnormalities, transposition of the great arteries, tetralogy of Fallot, ventricular septal defect, atrial septal defect, hypoplastic left heart syndrome), level 1 pregnancy sickness in the mother was associated with a slightly reduced risk for congenital heart defects in the offspring. The effect was most pronounced for the defects of septal closure, atrial septal defect, and ventricular septal defect, and was statistically significant only for atrial septal defect. For most of these defects, with the exception of tetralogy of Fallot and hypoplastic left heart syndrome, the risk was lower in the subgroup of antinausea medication users although this difference did not reach statistical significance. For several defects (common truncus arteriosus, atrioventricular septal defect, and pulmonary atresia), level 1 NP was not associated with a reduced risk; in fact, it was associated with a slightly higher risk which was not statistically significant. For tricuspid atresia, the risk was similar to that in the reference group. As with other defects, in the subgroup of mothers who took an antinausea medication, the risk of giving birth to a child with one of these defects tended to be lower than among mothers who did not take medications. However, once more, the differences were not statistically significant.
DISCUSSION
In this study, we found that report of nausea that started within the first 2 months of pregnancy, was daily, and lasted 2 months or more was associated with a reduced risk of giving birth to a child with a congenital heart defect. This effect tended to disappear with less severe levels of nausea and this trend was statistically significant. In addition, the group of mothers who had early nausea and used antinausea medication had a lower risk of giving birth to a child with a congenital heart defect than did those who did not use medication or those who had no nausea during pregnancy. For all congenital heart defects, as a group, this effect was most pronounced when the antinausea medication was Bendectin®. Among individual heart defects, level 1 NP was associated with a statistically significant lower risk only for atrial septal defects. For most individual heart defects reported here, with the exception of tetralogy of Fallot and hypoplastic left heart syndrome, a lower relative risk was observed among children of mothers who used antinausea medication compared with the children of mothers who had nausea but did not use antinausea medication; however, this reduction in risk did not reach statistical significance. The lower relative risk for congenital heart defects among children of medication users may be because such users had more severe nausea not measured by our scale, or because of some specific effect of the medications used.
In interpreting the study results and discussing the possible reasons for the reported associations, we should consider the study's potential strengths and limitations. The major strength of this study is that it was population-based and had a large number of case and control infants. Its limitations include difficulties in quantifying the severity of nausea and separating effects of nausea from effects of antinausea medications, and the long interval between the birth of a child and the mother's interview. Recall bias was unlikely to contribute significantly to the association in this study. It has been suggested that mothers of infants with birth defects, in search of a reason for the defect, would recall events related to pregnancy better than mothers of infants without birth defects, hi such case, mothers of infants with congenital heart defects might have recalled nausea during pregnancy and use of antinausea medications better and more often than mothers of babies without congenital heart defects. Therefore, if there was any recall bias, it would have acted against this association, not in its favor, and the association found in our study may have been underestimated. To control for potential confounding, we adjusted for a number of covariates (table 1) and the odds ratios did not change to an appreciable degree. However, unmeasured factors, such as differential pregnancy loss, resulting in changes in the prevalence of congenital heart defects at birth, may have contributed to the association. Some of our findings are consistent with previous studies on nausea and vomiting of pregnancy. Like other researchers, we found that about 70 percent of pregnant women reported nausea during pregnancy (2, 5, 6) . The association between NP and congenital heart defects has not been studied in detail previously. Pettiti (2) found that among women without nausea during the first trimester the relative risk of having a child with a major anomaly was 1.3 (95 percent CI 0.9-1.9). The Baltimore-Washington Infant Study found a slightly reduced risk for congenital heart defects (OR = 0.90, 95 percent CI 0.82-1.00) among the children of mothers who reported first trimester morning sickness but did not examine the associations between severity of maternal morning sickness and the risk for congenital heart defects among the children (16) .
Studies on prenatal loss provide some indirect evidence for possible association between absence of morning sickness in the mother and a congenital heart defect in the fetus or child. Congenital heart defects are more frequent in spontaneous abortions and stillborn fetuses (7), even after excluding cases with chromosomal anomalies, and spontaneous abortions appear to be more frequent among women who do not experience nausea and vomiting of pregnancy (2-6) or who have lower blood levels of pregnancy hormones such as human chorionic gonadotropin (hCG) (17) (18) (19) (20) . In addition, bleeding or spotting during pregnancy, a sign of threatened abortion, was associated with a slightly higher risk of giving birth to a child with a congenital heart defect (OR = 1.18, 95 percent CI 1.04-1.34) in the Baltimore-Washington Infant Study (16) . Similarly, higher risks for congenital heart defects in the child have also been found among mothers treated with female sex hormones (21-23), mainly progestogenshormonal preparations that may be used for treatment of threatened abortion in early pregnancy but are not known to have a proven teratogenic effect in animals.
What are the possible reasons for the inverse association that we observed between a mother's reporting of early, frequent, and long-lasting nausea and the risk for occurrence of a congenital heart defect in her child? Could nausea during pregnancy, or what it is a marker for, be responsible for this association? Although nausea and vomiting occur very frequently in pregnancy, the pathophysiology of this condition is still not well understood. It has been linked to higher blood levels of hCG (17, 18, 24) and to the steroid hormones progesterone and estradiol (25) , although the latter hypothesis has less support in the literature. With onset of symptoms at 5.5 gestational weeks, peak in symptoms at 9 weeks, and cessation around 13 weeks, as demonstrated in a prospective study (5) , nausea and vomiting during pregnancy seem to follow the pattern of betahCG blood levels, characterized by sharp increase around 4-5 gestational weeks, a peak at approximately 10 gestational weeks, and decrease around 12 gestational weeks (26, 27) . A number of other pregnancyspecific peptides and growth factors are also increased in maternal circulation during early pregnancy. At least two peptides (placental peptide 14 and inhibin) parallel in time the hCG secretion pattern, while another growth factor, activin, is believed to stimulate hCG secretion (26) but the relation between nausea and vomiting of pregnancy and these peptides and growth factors has not been studied. Whether any of these hormones or growth factors play a role in human heart development is unclear.
Although we must be very cautious in interpreting our findings, there is some indirect evidence in the literature to raise the hypothesis that, indirectly, a link may exist between maternal nausea during pregnancy (i.e., level of pregnancy hormones and growth factors) and embryonic heart development. A recent study showed that hCG may play a role in gap junctional cell-to-cell communication (28) which is essential in cell differentiation and is mediated by channels composed of special proteins called connexins (29) . Experiments in mice showed that knocking out the connexin43 gene caused severe heart defects in mice (30) . However, to our knowledge, the effect of hCG on cell-to-cell communication in the developing heart has not been studied. In animal studies, activin stimulates heart formation (31) and appears to play a role in the determination of left-right asymmetry and orientation of the heart (32). It is interesting that, in our study, the risk for looping abnormalities of the heart (which include anomalies of the left-right orientation of the heart and its segments), was reduced among the children of mothers who reported level 1 nausea and used antinausea medications, but this reduced risk was not statistically significant (table 4) . We could speculate that disruption in hormonal and/or growth factor secretion could cause the absence of nausea as well as problems in fetal heart development or, in other words, genetic and/or environmental factors may affect both the secretion of pregnancy-specific hormones and/or growth factors and heart development.
Another intriguing finding in our study was the apparent lower risk for congenital heart defects among children whose mothers used antinausea medications. One possible explanation is that women who took medications probably had more severe nausea which could not be captured by our scale of severity (for instance, we had no information on vomiting and its frequency). Another possible explanation is that the reduced risk could have been associated with the antinausea medication itself. The medication most often used was Bendectin®. It was the most frequently prescribed antinausea medication before 1983. Results from a recent meta-analysis showed that, for a number of congenital defects, maternal use of Bendectin® during pregnancy was not associated with an increased risk and, for two defects, oral clefts and congenital heart defects, the pooled relative risk was slightly reduced (33) . In one study on teratogenicity of anti-nausea medications (34), the frequency of major congenital anomalies diagnosed by one year of age was lower among children whose mothers used Bendectin® than among children whose mothers did not use antinausea medications or those whose mothers did not report nausea and/or vomiting (1.6 percent, 2.2 percent, and 2.6 percent, respectively); this finding, however, was not discussed by the authors.
Bendectin® was composed of doxylamine succinate 10 mg, dicyclomine 10 mg (dropped from the formulation in 1976), and pyridoxine (vitamin B 6 ) 10 mg. Vitamin B 6 alone has been used for treatment of nausea and vomiting of pregnancy (35, 36) and pregnant women are considered to have increased needs for vitamin B 6 (37) but it is not known whether women with nausea and vomiting are vitamin B 6 deficient. It is also unknown whether mothers' use of vitamin B 6 alone may reduce their children's risk for congenital heart defects. Vitamin B 6 deficiency in animals has been found to have teratogenic effects, although no anomalies of the cardiovascular system have been described (38) . Animal studies show that some chemicallyinduced birth defects (cleft palate) can be prevented by vitamin B 6 (39) . In humans, several studies demonstrate that mothers' use of multivitamins periconceptionally is associated with a reduced risk for conotruncal heart defects (40, 41) and defects of septal closure (42) among their children. Speculation has been that the effect was probably due to folic acid but it could, as well, be due to other vitamins in the multivitamin preparation. Vitamin B 6 in a dose of 2 to 3 mg is contained in virtually all multivitamin preparations. It is important to note that Bendectin® contained 10 mg of vitamin B, and the usual recommended dose was two to D three tablets per day. Thus, women who took it were taking, on the average, a dose eight or more times higher than the currently recommended daily amount of 1.9 mg of vitamin B 6 for pregnant women (43) . Theoretically it is possible, though less likely, that the other components of Bendectin®, may have contributed to the lower risk associated with the use of Bendectin®.
In our study, the most severe nausea (level 1) was associated with some reduced risk for the following types of individual congenital heart defects: looping abnormalities, transposition of the great arteries, tetralogy of Fallot, hypoplastic left heart syndrome, and defects of septal closure, but the reduced risk was statistically significant only for atrial septal defects. For several other defects (common truncus arteriosus, atrioventricular septal defect, and pulmonary atresia), the risk was slightly increased but this was not statistically significant. If variations of hormonal, growth factor, or metabolite levels play a role in the genesis of heart defects for which nausea was associated with lower risk, the defects from this group may be potentially preventable. It was interesting, however, that even for defects for which nausea itself was not associated with a decreased risk, the risk tended to be lower when an antinausea medication was used.
In brief, the hypotheses that we suggest to explain the association between mothers' history of nausea during pregnancy and their children's risk for congenital heart defects could be summarized as follows: nausea during early gestation is a marker of normal production of pregnancy hormones and pregnancyspecific growth factors, either of which may play a role in heart development. There may be common genetic or environmental factors that cause insufficient production of these hormones and/or growth factors as well as abnormal heart development. A possible reason for the lower risk for congenital heart defects among children of mothers with nausea who took antinausea medication may be that diey had more severe nausea, which could not be quantified by our scale; alternatively, maternal use of high dose of vitamin B 6 (contained in Bendectin®) may have had a protective effect on the embryonic heart development.
If the associations found in this study are confirmed by other studies, future investigation into the underlying mechanisms could help elucidate some pathogenetic aspects of congenital heart defects as well as reveal opportunities for primary prevention of these serious and very common congenital defects.
